Earlier today, I commented on Eli Lilly’s CEO request for greater adoption of HIT and subsequent sharing of aggregate, anonymous patient data to assist in identifying potential adverse drug events (ADE).

Well, low and behold the latest issue of Government Health IT reports that a recent study found current HIPAA rules is making it more cumbersome for researchers to do epidemiological studies.

Looks like it may be a long slog to achieve that Taurel’s vision.